Skip to content

Telomerase gene therapy

A viral vector carrying the telomerase gene, offered through a patient-paid study abroad. The registry entry has not been updated since 2019 and no results exist.

Gene & frontier therapiesgene therapyEarly stage

Availability Clinical trials only

What it is

Telomeres cap chromosomes and shorten as cells divide. Telomerase, encoded by the hTERT gene, rebuilds them. This therapy uses an adeno-associated virus to deliver hTERT into a person's cells, on the theory that lengthening telomeres reverses a hallmark of aging. It is not reversible.

Why people choose this treatment

Telomere shortening is the most legible story in aging biology, and telomerase is the enzyme that undoes it. That clarity is the whole appeal. The very few who pursued it were buying the mechanism; there is no demonstrated outcome to buy.

How it's delivered

There is no legitimate route to this. The only offer of record is Libella Gene Therapeutics, which announced in 2019 a Phase 1 study at a clinic in Colombia with a participation fee of one million dollars. Paying to enter a trial inverts how research works, and bioethicists said so.

Where the evidence stands

Nothing in humans. The registry record, NCT04133649, lists five estimated participants, single-arm, no masking, status unknown since December 2019, and no posted results. Work from María Blasco's lab showed AAV-delivered telomerase extending lifespan in mice; that is where the idea comes from and where it stops. Telomerase also carries an unresolved cancer question, since most tumors reactivate it. Treat any claim of reversed biological age as unsupported.

Estimated cost

  • $1,000,000 announced participation fee
  • Participants pay to enter, not the reverse
  • No results have ever been posted
  • Not covered by insurance

Who offers it

Nobody offers this legitimately. Libella Gene Therapeutics is the sole sponsor of record, outside FDA oversight by design, with a registry entry dormant since 2019.

How we know

Recorded from the trial registry and contemporaneous reporting on our last research pass. We list no referral path to this treatment and are not compensated for this entry.

Go deeper

Our regenerative therapies hub covers gene therapy for aging, what would count as real evidence, and why the mouse-to-human gap is so hard to cross.

Longevity.io is for educational purposes only and is not medical advice. We list this treatment so the record is clear, not because it is an option worth weighing: an irreversible viral gene therapy with no published human safety data belongs in a properly funded trial, not on a price list. Confirm any claim you encounter against the registry itself.

Your Longevity Blueprint

Build your starting plan.

A few short questions, about two minutes. The Blueprint recommends where to start and explains why.

Build my Blueprint